Sage Therapeutics, Inc.

Symbol: SAGE

NASDAQ

12.34

USD

Market price today

  • -1.4749

    P/E Ratio

  • 0.0371

    PEG Ratio

  • 742.65M

    MRK Cap

  • 0.00%

    DIV Yield

Sage Therapeutics, Inc. (SAGE) Financial Statements

On the chart you can see the default numbers in dynamics for Sage Therapeutics, Inc. (SAGE). Companys revenue shows the average of NaN M which is NaN % gowth. The average gross profit for the whole period is NaN M which is NaN %. The average gross profit ratio is NaN %. The net income growth for the company last year performance is NaN % which equals NaN % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Sage Therapeutics, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to . A look back at the past year reveals a total asset change of NaN. Shareholder value, as depicted by the total shareholder equity, is valued at NaN in the reporting currency. The year over year change in this aspect is NaN%.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012

balance-sheet.row.cash-and-short-term-investments

0753.21272.51742.3
2101.3
1010.8
922.8
518.8
397.5
186.8
127.8
8.1
2.8

balance-sheet.row.short-term-investments

0682.21109.81448.1
438.5
881.7
731.8
212.6
229
0
0
0
0

balance-sheet.row.net-receivables

08313.718.5
0
0
0
0
0
0
0
0
0

balance-sheet.row.inventory

01.3-64.5-18.5
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-current-assets

031.850.858.3
22.8
26.7
21.9
6.2
5.1
1.7
1.1
0.3
0

balance-sheet.row.total-current-assets

0869.41272.51800.6
2122.4
1035.1
944.7
525.1
402.6
188.5
128.8
8.4
2.8

balance-sheet.row.property-plant-equipment-net

06.413.419.1
31.8
42.9
8
4.9
2
0.3
0.2
0.1
0.1

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-investments

001.31.3
1.7
2.4
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0
0
0.6
0
0

balance-sheet.row.other-non-current-assets

06.569.34.3
3.3
3.8
0
0
0
0.2
0
0
0

balance-sheet.row.total-non-current-assets

012.98424.6
36.9
49.1
8
4.9
2
0.5
0.8
0.1
0.2

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

0882.31356.41825.3
2159.2
1084.2
952.7
529.9
404.5
189
129.7
8.5
3

balance-sheet.row.account-payables

010.318.910.4
3.7
15.3
34
9.3
12.8
5.2
2.4
2
1.3

balance-sheet.row.short-term-debt

05.27.67.5
8.7
10.2
0
0
0
0
0
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

004.511
19.4
26.8
0
0
0
0
0
0
0

Deferred Revenue Non Current

0000
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

067.372.767.3
54.9
86.6
52
42.6
22.4
10.1
5.3
0.3
0.1

balance-sheet.row.total-non-current-liabilities

004.611.1
19.7
27.4
3.7
2.5
0.8
0
0
37.8
15

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

05.212.118.4
28.1
37.1
0
0
0
0
0
0
0

balance-sheet.row.total-liab

082.7103.896.3
86.9
139.5
89.7
54.5
36
15.3
7.8
40.1
16.4

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
129.7
37.7
0

balance-sheet.row.common-stock

0000
0
0
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

0-2569.7-2028.2-1495.4
-1037.5
-1643.6
-963.3
-590.4
-320.3
-161.3
-66.8
-31.7
-13.4

balance-sheet.row.accumulated-other-comprehensive-income-loss

0-0.8-10.2-2.7
0.4
1.3
-0.5
0
-0.1
-0.3
-0.1
-0.1
0

balance-sheet.row.other-total-stockholders-equity

0337032913227.1
3109.4
2586.9
1826.8
1067
689.4
335.3
59.2
-37.5
0

balance-sheet.row.total-stockholders-equity

0799.51252.61729
2072.3
944.7
863
475.5
368.5
173.7
121.9
-31.5
-13.4

balance-sheet.row.total-liabilities-and-stockholders-equity

0882.31356.41825.3
2159.2
1084.2
952.7
529.9
404.5
189
129.7
8.5
3

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

0799.51252.61729
2072.3
944.7
863
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-

Total Investments

0682.21109.81448.1
438.5
881.7
731.8
212.6
229
0
0
0
0

balance-sheet.row.total-debt

05.212.118.4
28.1
37.1
0
0
0
0
0
0
0

balance-sheet.row.net-debt

0-65.8-150.6-275.8
-1633
-89.6
-190.9
-306.2
-168.5
-186.8
-127.8
-8.1
-2.8

Cash Flow Statement

The financial landscape of Sage Therapeutics, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of NaN. The company recently extended its share capital by issuing NaN, marking a difference of NaN compared to the previous year. The company's investing activities resulted in net cash usage, amounting to NaN in the reporting currency. This is a shift of NaN from the previous year. In the same period, the company recorded NaN, NaN, and NaN, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of NaN, with a year over year difference of NaN. Furthermore, the company allocated NaN for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as NaN, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012

cash-flows.row.net-income

0-541.5-532.8-457.9
606.1
-680.2
-372.9
-270.1
-159
-94.5
-33.8
-18.3
-9.6

cash-flows.row.depreciation-and-amortization

01.41.14.2
2.6
2.3
1.1
0.5
0.3
0.1
0.1
0
0

cash-flows.row.deferred-income-tax

0000
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

073.461.6104.6
96
153.2
102
35.5
23
15.2
2.5
0.1
0

cash-flows.row.change-in-working-capital

0-67.45.7-18.5
-39.7
6.7
19.2
15.2
17.5
7.2
4.1
0.6
0.7

cash-flows.row.account-receivables

0-69.34.8-18.5
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

069.3-4.818.5
0
0
0
0
0
0
0
0
0

cash-flows.row.account-payables

0-8.58.46.7
-11.5
-18.8
24.5
-3.7
7.8
2.7
0.4
0.7
0.6

cash-flows.row.other-working-capital

0-58.9-2.8-6.7
-28.2
25.4
-5.3
18.9
9.7
4.6
3.6
-0.1
0.1

cash-flows.row.other-non-cash-items

0-6.54.4-10.6
-0.7
-10.6
-10.1
-0.4
-0.5
1.2
0.1
0.1
0

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-0.6-0.9-0.4
-0.3
-5.8
-2.9
-1.4
-1.4
-0.2
-0.1
0
-0.1

cash-flows.row.acquisitions-net

0-442.9-326.41002.1
-443
137.4
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

0-594.7-881-1990.2
-458.7
-1308.7
-1484.4
-244.4
-259.1
0
0
0
0

cash-flows.row.sales-maturities-of-investments

01038.11207.4988.1
901.7
1171.3
974.8
261.2
30.5
0
0
0
0

cash-flows.row.other-investing-activites

0442.9326.4-1002.1
443
-137.4
0
-0.3
-0.5
0
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

0442.9325.4-1002.4
442.7
-143.2
-512.5
15.2
-230.5
-0.2
-0.1
0
-0.1

cash-flows.row.debt-repayment

0-7-6.3-5.7
-6.8
-2.8
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

06.93.114.7
417.5
561.3
631.5
326
330.2
129.7
96.3
0.1
0

cash-flows.row.common-stock-repurchased

0-0.90-1.4
0
-2.2
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

00-3.2-7.6
0
-0.6
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

06.19.513.3
16.1
52
27.9
15.8
0.8
0.1
50.6
22.7
9

cash-flows.row.net-cash-used-provided-by-financing-activities

063.113.3
426.8
607.6
659.4
341.8
331
129.9
146.9
22.8
9

cash-flows.row.effect-of-forex-changes-on-cash

0540.600
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

0-91.6-131.5-1367.3
1533.7
-64.2
-113.8
137.7
-18.2
59
119.7
5.3
0

cash-flows.row.cash-at-end-of-period

072.3164295.5
1662.8
129.1
193.3
306.2
168.5
186.8
127.8
8.1
2.8

cash-flows.row.cash-at-beginning-of-period

0164295.51662.8
129.1
193.3
307.1
168.5
186.8
127.8
8.1
2.8
2.8

cash-flows.row.operating-cash-flow

0-540.6-460-378.2
664.3
-528.7
-260.7
-219.3
-118.7
-70.7
-27
-17.5
-8.9

cash-flows.row.capital-expenditure

0-0.6-0.9-0.4
-0.3
-5.8
-2.9
-1.4
-1.4
-0.2
-0.1
0
-0.1

cash-flows.row.free-cash-flow

0-541.1-461-378.6
663.9
-534.5
-263.5
-220.6
-120.1
-70.9
-27.2
-17.5
-9

Income Statement Row

Sage Therapeutics, Inc.'s revenue saw a change of NaN% compared with the previous period. The gross profit of SAGE is reported to be NaN. The company's operating expenses are NaN, showing a change of NaN% from the last year. The expenses for depreciation and amortization are NaN, which is a NaN% change from the last accounting period. Operating expenses are reported to be NaN, which shows a NaN% year-over-year change. Selling and marketing expenses are NaN, which is a NaN% change compared to the previous year. The EBITDA based on the recent numbers is NaN, representing a NaN% year-over-year growth. The operating income is NaN, which shows a NaN% change when compared to the previous year. The change in the net income is NaN%. The net income for the last year was NaN.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012

income-statement-row.row.total-revenue

086.57.76.3
1114.2
6.9
90.3
0
0
0
0
0
0

income-statement-row.row.cost-of-revenue

02.20.80.6
0.6
0.4
0
0
0
0
0
0
0

income-statement-row.row.gross-profit

084.36.95.8
1113.6
6.5
90.3
0
0
0
0
0
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0-0.400.1
0.3
0.1
0
-0.1
0
0
0
0
0

income-statement-row.row.operating-expenses

0630.8553.9466.7
489.7
714.6
483.5
273.2
160.2
94.7
33.8
18.3
9.6

income-statement-row.row.cost-and-expenses

0632.9554.7467.2
490.2
715
483.5
273.2
160.2
94.7
33.8
18.3
9.6

income-statement-row.row.interest-income

038.714.22.9
9.6
27.8
20.3
3.1
1.2
0.2
0
0
0

income-statement-row.row.interest-expense

0014.20
0
0
0
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0-33.814.23
9.8
27.9
0
-0.1
0
0
0
0
0

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0-0.400.1
0.3
0.1
0
-0.1
0
0
0
0
0

income-statement-row.row.total-operating-expenses

0-33.814.23
9.8
27.9
0
-0.1
0
0
0
0
0

income-statement-row.row.interest-expense

0014.20
0
0
0
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

01.41.14.2
55.5
2.3
1.1
0.5
0.3
0.1
0.1
0
0

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

0-579.8-547-460.9
596.2
-708.1
-393.2
-273.2
-160.2
-94.7
-33.8
-18.3
-9.6

income-statement-row.row.income-before-tax

0-541.5-532.8-457.9
606.1
-680.2
-372.9
-270.1
-159
-94.5
-33.8
0
-9.6

income-statement-row.row.income-tax-expense

0-5.4-29.5-7.1
15.5
-30.1
20.4
-3.6
-1.5
-0.3
-0.1
0
0

income-statement-row.row.net-income

0-541.5-503.3-450.8
606.1
-650.2
-372.9
-270.1
-159
-94.5
-33.8
-18.3
-9.6

Frequently Asked Question

What is Sage Therapeutics, Inc. (SAGE) total assets?

Sage Therapeutics, Inc. (SAGE) total assets is 882277000.000.

What is enterprise annual revenue?

The annual revenue is N/A.

What is firm profit margin?

Firm profit margin is 0.965.

What is company free cash flow?

The free cash flow is -7.068.

What is enterprise net profit margin?

The net profit margin is -5.525.

What is firm total revenue?

The total revenue is -5.946.

What is Sage Therapeutics, Inc. (SAGE) net profit (net income)?

The net profit (net income) is -541489000.000.

What is firm total debt?

The total debt is 5165000.000.

What is operating expences number?

The operating expences are 630759000.000.

What is company cash figure?

Enretprise cash is 0.000.